Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Return on Equity (2022 - 2025)

Corvus Pharmaceuticals has reported Return on Equity over the past 4 years, most recently at 0.15% for Q3 2025.

  • Quarterly results put Return on Equity at 0.15% for Q3 2025, up 156.0% from a year ago — trailing twelve months through Sep 2025 was 0.15% (up 156.0% YoY), and the annual figure for FY2024 was 1.66%, down 120.0%.
  • Return on Equity for Q3 2025 was 0.15% at Corvus Pharmaceuticals, up from 0.64% in the prior quarter.
  • Over the last five years, Return on Equity for CRVS hit a ceiling of 0.15% in Q3 2025 and a floor of 2.63% in Q4 2024.
  • Median Return on Equity over the past 4 years was 0.6% (2023), compared with a mean of 0.82%.
  • Biggest five-year swings in Return on Equity: crashed -210bps in 2024 and later surged 156bps in 2025.
  • Corvus Pharmaceuticals' Return on Equity stood at 0.54% in 2022, then increased by 3bps to 0.52% in 2023, then crashed by -401bps to 2.63% in 2024, then skyrocketed by 94bps to 0.15% in 2025.
  • The last three reported values for Return on Equity were 0.15% (Q3 2025), 0.64% (Q2 2025), and 0.91% (Q1 2025) per Business Quant data.